Form 4: Indivior Director Receives Stock Grant

Indivior Pharmaceuticals, Inc. reports a stock grant to Director Mark Stejbach, comprising 6,518 Restricted Stock Units.

Summary

• Mark Stejbach, a Director at Indivior Pharmaceuticals, Inc., was granted 6,518 Restricted Stock Units (RSUs) on May 13, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's common stock each.
• The RSUs are set to vest on the day immediately preceding the date of the annual stockholders' meeting following the grant date.
• Vesting is contingent upon Mr. Stejbach's continued service to Indivior on the vesting date.
• Following this transaction, Mr. Stejbach beneficially owns 27,087 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard stock grant to a director, which is a routine part of executive compensation and does not inherently signal positive or negative company performance.

Positives

• Director Mark Stejbach received a grant of 6,518 Restricted Stock Units, indicating continued investment in the company's future by its leadership.
• The grant is structured to vest based on continued service, aligning management's interests with the company's long-term performance.
• Mr. Stejbach directly beneficially owns 27,087 shares of common stock, demonstrating a significant personal stake in Indivior.

Risks

• The vesting of RSUs is contingent on continued service, meaning any departure from the company before the vesting date would result in forfeiture of the grant.
• The value of the RSUs is tied to the future performance of Indivior's common stock, which is subject to market volatility and company-specific risks.

Future Outlook

The Restricted Stock Units granted to Director Mark Stejbach are scheduled to vest on the day immediately preceding the date of the annual stockholders' meeting following the grant date, subject to his continued service.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) to directors are a common form of executive compensation in the pharmaceutical industry, designed to incentivize long-term performance and align leadership interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation and does not immediately dilute share ownership. However, the vesting of these units will result in the issuance of new shares, potentially impacting future earnings per share.
• Employees: This filing is specific to a director's compensation and has no direct impact on other employees.
• Management: The grant aligns the director's interests with long-term company performance through continued service requirements for vesting.

Next Steps

• Director Mark Stejbach must continue his service to Indivior until the vesting date to receive the shares underlying the RSUs.
• The RSUs will vest on the day immediately preceding the date of the annual stockholders' meeting following the grant date.

Key Dates

Keywords

Indivior Pharmaceuticals, INDV, Form 4, Stock Grant, Restricted Stock Units, RSUs, Director Compensation, Beneficial Ownership, SEC Filing